BQPrime
•75% Informative
The Bengaluru-ba 31% year-on-year net Rs 313 attributa the March quarter rs rose 31% Biocon Ltd. r to Rs 313 crore over 17 months uart Wednesday t compares fourth-quarter 0 crore consensus estimate of analysts Bengaluru by Bloomberg. 8.6 31% s year-on-year clas Rs 313 maryFeed_h the March quarter Gi">12-month 270 Gi">Bloomberg Bloomberg xt__NxlGi">three 38% _ year-on-year t__N Rs 11,550 r the year ed_highLig Rs 217 __NxlGi">14 Bicara yFeed_highLightText__NxlGi">21the year c Biocon Ltd. ryFeed_highLightText__NxlGi">70Rs 800 span class= approximately $98 million t__NxlG Edelweiss Alternate Asset Advisors Ltd. eed_highLightText__NxlGi">8.7 Rs 500 ighLightText__NxlGi">the day Rs 300 Feed_highL Biocon Biologics Ltd. Nifty a transformational year highLightText__NxlGi">0.01% Viatris _NxlGi">10:02 a.m. Biocon Feed_highLightText__NxlGi">3.94% Kiran Mazumdar-Shaw yFeed_highLightText__NxlGi" Biocon da Biocon Q4 Consolidated ry YoY d_highLightTe 57% _Nxl Rs 3,773 uch as 7. Bloomberg > 3,615 maryFeed_ Ebitda ghtT 69% __Nx Rs 997 ioconBloomberg n class="summa 862 eed_highL Ebitda xt__NxlGi"> 26.4% iscal en 24.6% 02 Bloomberg 23.9% mmaryFeed_highLig 31% ext_ Rs 313 ">Rs 1.50 Bloomberg Rs 270
VR Score
87
Informative language
95
Neutral language
81
Article tone
formal
Language
English
Language complexity
38
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links